A Single Arm, Exploratory Clinical Study on the Prevention of Bone Marrow Suppression Caused by Platinum Containing Chemotherapy in Advanced Non-small Cell Lung Cancer With Trilaciclib

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis of non-small cell lung cancer(NSCLC), 40 eligible subjects who met the inclusion criteria were screened and given a treatment regimen of trilaciclib before chemotherapy, after signing informed consent.

Start Date30 Apr 2024

Sponsor / Collaborator

Henan Cancer Hospital

[+1]

NCT06364904 / Not yet recruitingPhase 3IIT

A Multicenter, III Stage, Randomized Controlled Trail on the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib in Untreated Unresectable and Metastatic Urothelial Carcinoma.

The aim of this study is to see whether the Trilaciclib is safe and effective in slowing down the growth of bladder cancer in patients while taking chemoimmunotherapy.

Start Date15 Apr 2024

Sponsor / Collaborator

Sun Yat-Sen Memorial Hospital

ChiCTR2400082382 / RecruitingPhase 4IIT

A Multi-Cohort, Open-Label, Exploratory Clinical Study of Trilaciclib in Myeloprotection in First-Line Combination Chemotherapy Regimens for Advanced Solid Tumors

Start Date01 Apr 2024

Sponsor / Collaborator-

100 Clinical Results associated with Trilaciclib Dihydrochloride

100 Translational Medicine associated with Trilaciclib Dihydrochloride

100 Patents (Medical) associated with Trilaciclib Dihydrochloride

Literatures (Medical) associated with Trilaciclib Dihydrochloride

01 Feb 2024·Pharmacological research

Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update

Review

Author: Roskoski, Robert

Owing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century. There are 80 FDA-approved therapeutic agents that target about two dozen different protein kinases and seven of these drugs were approved in 2023. Of the approved drugs, thirteen target protein-serine/threonine protein kinases, four are directed against dual specificity protein kinases (MEK1/2), twenty block nonreceptor protein-tyrosine kinases, and 43 inhibit receptor protein-tyrosine kinases. The data indicate that 69 of these drugs are prescribed for the treatment of neoplasms. Six drugs (abrocitinib, baricitinib, deucravacitinib, ritlecitinib, tofacitinib, upadacitinib) are used for the treatment of inflammatory diseases (atopic dermatitis, rheumatoid arthritis, psoriasis, alopecia areata, and ulcerative colitis). Of the 80 approved drugs, nearly two dozen are used in the treatment of multiple diseases. The following seven drugs received FDA approval in 2023: capivasertib (HER2-positive breast cancer), fruquintinib (metastatic colorectal cancer), momelotinib (myelofibrosis), pirtobrutinib (mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma), quizartinib (Flt3-mutant acute myelogenous leukemia), repotrectinib (ROS1-positive lung cancer), and ritlecitinib (alopecia areata). All of the FDA-approved drugs are orally effective with the exception of netarsudil, temsirolimus, and trilaciclib. This review summarizes the physicochemical properties of all 80 FDA-approved small molecule protein kinase inhibitors including the molecular weight, number of hydrogen bond donors/acceptors, polar surface area, potency, solubility, lipophilic efficiency, and ligand efficiency.

01 Feb 2024·Lung cancer (Amsterdam, Netherlands)

Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)

Article

Author: Chen, Hualin ; Liu, Qun ; Hu, YanPing ; Min, XuHong ; Yang, Yang ; Fan, Yun ; Li, Xiucui ; Yu, GuoHua ; Liu, BaoGang ; Zhang, XiQin ; Pan, YueYin ; Huang, Dingzhi ; Fan, HuiJie ; Yao, WenXiu ; Wu, Lin ; Dong, XiaoRong ; He, ZhiYong ; Ma, Rui ; Wang, QiMing ; Liu, Ying ; Ge, XiaoSong ; Yang, Chen ; Xu, Fei ; Cheng, Ying ; Zhou, Li

INTRODUCTION:

Trilaciclib is a transient cyclin-dependent kinase 4/6 inhibitor that decreases the incidence of chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC). TRACES study was designed to assess the safety, efficacy and pharmacokinetics (PK) of trilaciclib before chemotherapy in Chinese patients with ES-SCLC.

METHODS:

The study included an open-label safety run-in part (Part 1) and double-blinded, placebo-controlled part (Part 2) where patients received trilaciclib or placebo before chemotherapy. Treatment-naïve or previously treated ES-SCLC patients received intravenous trilaciclib (240 mg/m²) or placebo before etoposide/carboplatin or topotecan, respectively. Primary endpoints were PK, safety and duration of severe neutropenia (DSN) in Cycle 1 in Part 1 and Part 2. Exploratory endpoints included the effect of trilaciclib on other myeloprotection endpoints, safety and antitumor efficacy.

RESULTS:

Overall, 95 Chinese patients were enrolled, of which 12 and 83 patients were in Part 1 and Part 2, respectively. In Part 1, trilaciclib was well tolerated. Non-compartmental analysis results revealed no substantial differences in the main exposure parameters. In Part 2, 41 patients received trilaciclib, and 42 received placebo. Patients in trilaciclib arm vs placebo arm had a clinically and statistically significant decrease in DSN (mean [SD]) in Cycle 1 (0 [1.7] vs 2 [3.0] days; P = 0.0003), with improvements in additional neutrophil, red blood cell, and platelet measures. After a median follow-up of 14.1 months, the median overall survival was 12.0 months in trilaciclib arm and 8.8 months in placebo arm (HR, 0.69; 95 % CI: 0.40-1.22). Median progression-free survival was 4.8 months and 4.3 months, respectively (HR, 0.86; 95 % CI: 0.53-1.39). Trilaciclib had a well-tolerated safety profile.

CONCLUSIONS:

Trilaciclib in the Chinese population demonstrated a similar PK and safety profile as seen in other global trials. There was significant reduction of DSN in Cycle 1, thereby substantiating the myeloprotective effects of trilaciclib in Chinese ES-SCLC patients.

01 May 2024·Anti-cancer agents in medicinal chemistry

An Expedition on Synthetic Methodology of FDA-approved Anticancer Drugs (2018-2021)

Review

Author: Gupta, Ghanshyam Das ; Jain, Ankit ; Vishakha, S ; Verma, Sant Kumar ; Navneesh, N ; Patel, Preeti ; Kurmi, Balak Das

Abstract::

New drugs being established in the market every year produce specified structures for selective biological targeting. With medicinal insights into molecular recognition, these begot molecules open new rooms for designing potential new drug molecules. In this review, we report the compilation and analysis of a total of 56 drugs including 33 organic small molecules (Mobocertinib, Infigratinib, Sotorasib, Trilaciclib, Umbralisib, Tepotinib, Relugolix, Pralsetinib, Decitabine, Ripretinib, Selpercatinib, Capmatinib, Pemigatinib, Tucatinib, Selumetinib, Tazemetostat, Avapritinib, Zanubrutinib, Entrectinib, Pexidartinib, Darolutamide, Selinexor, Alpelisib, Erdafitinib, Gilteritinib, Larotrectinib, Glasdegib, Lorlatinib, Talazoparib, Dacomitinib, Duvelisib, Ivosidenib, Apalutamide), 6 metal complexes (Edotreotide Gallium Ga-68, fluoroestradiol F-18, Cu 64 dotatate, Gallium 68 PSMA-11, Piflufolastat F-18, 177Lu (lutetium)), 16 macromolecules as monoclonal antibody conjugates (Brentuximabvedotin, Amivantamab-vmjw, Loncastuximabtesirine, Dostarlimab, Margetuximab, Naxitamab, Belantamabmafodotin, Tafasitamab, Inebilizumab, SacituzumabGovitecan, Isatuximab, Trastuzumab, Enfortumabvedotin, Polatuzumab, Cemiplimab, Mogamulizumab) and 1 peptide enzyme (Erwiniachrysanthemi-derived asparaginase) approved by the U.S. FDA between 2018 to 2021. These drugs act as anticancer agents against various cancer types, especially non-small cell lung, lymphoma, breast, prostate, multiple myeloma, neuroendocrine tumor, cervical, bladder, cholangiocarcinoma, myeloid leukemia, gastrointestinal, neuroblastoma, thyroid, epithelioid and cutaneous squamous cell carcinoma. The review comprises the key structural features, approval times, target selectivity, mechanisms of action, therapeutic indication, formulations, and possible synthetic approaches of these approved drugs. These crucial details will benefit the scientific community for futuristic new developments in this arena.

137

News (Medical) associated with Trilaciclib Dihydrochloride

26 Jun 2024

·www.prnewswire.com

Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EGFR) antibody drug developed in collaboration with Mabpharm Limited (2181.HK), has recently received approval from the China National Medical Administration (NMPA) for marketing. Enlituo® is indicated for use in combination with the FOLFIRI regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer (mCRC). According to the 'Cancer Incidence and Mortality in China, 2022' by the National Cancer Center, colorectal cancer ranks as the second most common cancer in China. Annually, there are 1.571 million new cases and 240,000 deaths, imposing a substantial disease burden on the society. When colorectal cancer patients develop metastasis, the primary treatment options often include chemotherapy and targeted drugs. Previous clinical studies have demonstrated the effectiveness of EGFR-targeting antibody drugs in treating malignant tumors, particularly mCRC, in patients without RAS/BRAF mutations (wild-type). Enlituo® (cetuximab beta, originally known as CMAB009) is a recombinant EGFR monoclonal antibody developed independently in China. Classified as a 2.4 class modified biological new drug, cetuximab beta is prepared using a proprietary protein expression technique, effectively avoiding glycosylation modification that may lead to hypersensitivity. Enlituo® received approval based on robust evidence from a phase 2/3 study and a phase 3 confirmatory clinical trial. In an open-label, randomized, controlled, multicenter, prospective phase 3 study, 505 subjects with RAS/BRAF wild-type mCRC were treated and analyzed. Clinical data revealed that combining cetuximab beta with FOLFIRI significantly extended progression-free survival (PFS) compared to FOLFIRI alone (13.133 months vs. 9.567 months, P = 0.004). Additionally, the combination increased the objective response rate (ORR) (69.1% vs. 42.3%, P < 0.001) and overall survival (OS) (2.322 years vs. 1.900 years, P = 0.024). Dr. Renhong Tang, Chairman of Simcere Zaiming, emphasized Enlituo®'s unique clinical value in targeted therapy: "Its initial indication for colorectal cancer addresses a large patient population. The product synergizes well with Simcere Zaiming's existing offerings, and efforts are underway to accelerate its commercialization, benefiting more cancer patients." Dr. Hao Wang, Chief Executive Officer of Mabpharm, expressed excitement as Enlituo® bridged the gap in colorectal cancer treatment with domestically developed EGFR-targeted drugs. "This provides clinicians and patients with updated therapeutic options. By collaborating with Simcere Zaiming's Marketing Team, we are able to rapidly realize the clinical value of Enlituo®, benefiting hundreds of thousands of patients in China with an effective and affordable biological new drug. " Enlituo represents the first EGFR monoclonal antibody drug developed in China with independent intellectual property rights that are approved for the first-line treatment of mCRC. The successful launch of Enlituo® will provide high quality and affordable biological targeted remedy for Chinese cancer patients. In March 2023, the drug marketing application of Enlituo® was accepted by the NMPA. On August 18, 2023, the Group entered into a cooperation agreement with Mabpharm, pursuant to which the Group obtained the exclusive commercial rights in respect of Enlituo® in Chinese mainland. About Mabpharm Mabpharm (stock code: 2181) focuses on the development of monoclonal antibodies and has an experienced R&D team, multiple core technologies, leading domestic large-scale antibody preparation system and excellent quality control system. Mabpharm strives to bring high quality and affordable innovative biologics through its efficient R&D system and low-cost pharmaceutical production capability to the market, and develops various therapeutic products by fully utilizing its extensive R&D experience. About Simcere Zaiming Simcere Zaiming, an oncology-centric biopharmaceutical subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096), was established in 2023. The company is devoted to crafting groundbreaking therapies aimed at fulfilling the unmet clinical needs of cancer patients globally. With a robust and innovative R&D pipeline featuring distinct clinical assets, Simcere Zaiming has successfully launched several products in China, including COSELA®, Endostar®, and Envafolimab. The company is determined to deliver potentially transformative treatment options to cancer patients worldwide through its internal R&D, manufacturing, and commercialization capabilities, complemented by strategic collaborations with leading partners in the field of innovative cancer therapeutics. SOURCE Simcere

Drug ApprovalPhase 3License out/inClinical ResultCSCO

24 Jun 2024

·firstwordpharma.com

G1 Therapeutics' Cosela fails to improve survival in pivotal TNBC study

G1 Therapeutics said Monday that the Phase III PRESERVE 2 study evaluating Cosela (trilaciclib) in triple-negative breast cancer (TNBC) failed to meet its primary overall survival (OS) endpoint. CEO Jack Bailey called the results “unexpected,” adding “we are disappointed that this trial did not deliver the benefit that we anticipated.”However, questions had been raised around the outcome of the study when G1 Therapeutics announced in February that it would continue to its final survival analysis, denting hopes of an early readout. The company had already pushed back an interim OS analysis from the second half of 2023 to the first half of 2024, as "the number of actual events appears to be occurring more slowly than predicted.”On Monday, G1 Therapeutics noted that median OS in the trilaciclib plus chemotherapy arm was 17.4 months compared to 17.8 months in the control arm, with a hazard ratio (HR) of 0.91. The drugmaker added that median OS numerically favoured the trilaciclib arm in both PD-L1 subgroups, although neither achieved statistical significance. The trial included 187 patients with locally advanced unresectable or metastatic TNBC who received first-line Cosela or placebo prior to chemotherapy with gemcitabine and carboplatin. Results from the study are expected to be presented at an upcoming medical meeting.Cosela was first approved by the FDA in 2021 to reduce the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy for extensive-stage small-cell lung cancer. The transient CDK4/6 inhibitor also gained approval in China for the same indication, where it is partnered with Simcere Pharmaceuticals.

Phase 3Drug ApprovalClinical ResultClinical Trial TerminationPhase 2

24 Jun 2024

·www.biospace.com

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT) Population The Company Will Focus its Efforts on the Global Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Market G1 is Sufficiently Funded to Achieve Anticipated Company Profitability in the Second Half of 2025 Management to Host Webcast and Conference Call Today at 8:30 AM ET RESEARCH TRIANGLE PARK, N.C., June 24, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaciclib administered prior to chemotherapy (gemcitabine and carboplatin; GCb) in patients with metastatic TNBC. The study did not demonstrate a statistically significant treatment effect in the ITT population (n=187) with a hazard ratio (HR) of 0.91 (p=0.884). The median OS in the trilaciclib plus GCb arm was 17.4 months compared to 17.8 months in the control arm. Median OS numerically favored the trilaciclib arm in both PD-L1 subgroups (positive and negative), though neither achieved statistical significance. Varying effects were observed across regions and patients who received different types of subsequent therapies; these findings will be evaluated further. The safety pro trilaciclib with GCb observed in the trial was consistent with prior studies, and no new safety signals were identified. Consistent with other trilaciclib studies, evidence of myeloprotection was observed, including a reduction in the occurrence of severe neutropenia, which occurred in 8% of patients who received trilaciclib compared to 29% of patients in the control arm. The Company will submit the results of this trial to a future medical conference. “The unexpected results from PRESERVE 2 underscore the challenge of developing new therapies for triple negative breast cancer,” said Jack Bailey, Chief Executive Officer of G1 Therapeutics. “We are disappointed that this trial did not deliver the benefit that we anticipated to people living with TNBC. We are also grateful to the patients who participated in this trial, their families, and their healthcare teams including the clinicians and their staff.” Mr. Bailey continued, “We will now further our focus on both accelerating and expanding the growth of the ES-SCLC business to achieve anticipated company profitability in the second half of 2025 and evaluating other myeloprotection uses for trilaciclib. We are also pursuing ex-US partners to expand the use of COSELA® (trilaciclib) globally.” Financial Guidance G1 today reaffirmed its full year 2024 COSELA net revenue guidance and updated its cash runway guidance. G1's guidance is based on current expectations for continued sales growth of COSELA in the U.S. and achievement of its forecasts. The Company expects to generate between $60 million and $70 million in COSELA net revenue in 2024. Additionally, G1 plans to wind down the Phase 3 PRESERVE 2 trial, discontinue the anticipated hiring of staff and investment for a 1L TNBC indication and make targeted headcount reductions outside of the existing commercial organization to streamline the Company. These efforts are expected to provide sufficient cash runway to achieve anticipated company profitability in the second half of 2025. Webcast and Conference Call G1 will host a webcast and conference call at 8:30 a.m. ET today to discuss PRESERVE 2. Please note the following process to access the call via telephone: To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended to join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the Company’s website: . The webcast will be archived on the same page for 90 days following the event. About G1 Therapeutics G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company whose mission is to develop and deliver next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1’s goal is to provide innovative therapeutic advances for people living with cancer. G1 is based in Research Triangle Park, N.C. For additional information, please visit and follow us on X (formerly known as Twitter) @G1Therapeutics and LinkedIn. G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and the COSELA logo are trademarks of G1 Therapeutics, Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," “could”, “believe,” “goal”, “projections,” "estimate," "intend," “indicate,” “potential,” “opportunity,” “suggest,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, expectations with respect to future performance and development and commercialization of our products, including our focus on ES-SCLC and ex-US partnering on COSELA (trilaciclib), our anticipated cash runway and profitability, and financial guidance for full year 2024. Each of these forward-looking statements involves significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Factors that may cause the company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein and include, but are not limited to, our dependence on the commercial success of COSELA (trilaciclib); the development and commercialization of new drug products is highly competitive; our ability to complete clinical trials for, obtain approvals for and commercialize any of its product candidates; our initial success in ongoing clinical trials may not be indicative of results obtained when these trials are completed or in later stage trials; the inherent uncertainties associated with developing new products or technologies and operating as a commercial-stage company; chemotherapy shortages and market conditions. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. We caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. G1 Therapeutics Contacts: Will Roberts Communications Officer Vice President, Investor Relations and Corporate Communications (919) 907-1944 wroberts@g1therapeutics.com

Phase 3Clinical ResultPhase 2

100 Deals associated with Trilaciclib Dihydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D11987	-	L01XE	DB15442

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Extensive stage Small Cell Lung Cancer	CN	Simcere Zaiming Pharmaceutical Co., Ltd.	30 Oct 2023
Chemotherapy-induced myelosuppression	US	G1 Therapeutics, Inc.	12 Feb 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Small Cell Lung Cancer	NDA/BLA	CN	Simcere Pharmaceutical Group Ltd.	01 Jun 2023
Triple Negative Breast Cancer	Phase 3	CN	Jiangsu Simcere Pharmaceutical Co., Ltd.	07 Dec 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	US	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	CN	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	AU	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	BG	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	FR	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	GE	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	MD	G1 Therapeutics, Inc.	15 Apr 2021
Metastatic Triple-Negative Breast Carcinoma	Phase 3	PL	G1 Therapeutics, Inc.	15 Apr 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04799249 (PRESERVE 2, Company_Website) Manual	Phase 3	Metastatic Triple-Negative Breast Carcinoma First line	187	Trilaciclib plus gemcitabine and carboplatin	ysehojzkxh(qmovtzytmk) = enzfdodwes fmezgbstlw (gupgfzouad ) Not Met	Negative	24 Jun 2024
				Placebo+ gemcitabine and carboplatin	ysehojzkxh(qmovtzytmk) = chmhpndeqf fmezgbstlw (gupgfzouad ) Not Met
NCT05113966 (ASCENT, ASCO2024) Manual	Phase 2	Triple Negative Breast Cancer human epidermal growth factor receptor 2-negative \| hormone receptor negative	30	Trilaciclib 240 mg/m2 + Sacituzumab govitecan 10 mg/kg	fphuxrnsbm(ojexjmkthh) = zwkoncmseo tbezwlumvi (dkvnerdgta, 9.9 - 42.3) View more	Positive	24 May 2024
NCT05112536 (CTgov)	Phase 2	Triple Negative Breast Cancer	24	Cylophosphamide+Carboplatin (Investigator discretion)+Trilaciclib+doxorubicin+paclitaxel+Pembrolizumab (Investigator discretion)	lhzyepdfoa(lezammiekf) = xppmxojtmh cbvgzfxqcd (zfrjxmyhbb, rjjlpesxug - krpastqyjv) View more	-	12 Mar 2024
G1T28-04 (NEWS) Manual	Phase 2	Triple Negative Breast Cancer ER Negative \| PR Negative \| HER2 Negative	102	曲拉西利和GCb (接受何种SACT)	aclltdgvyj(huoyhiypqi) = ccdsefmssi uwhxodutfk (fiewcpicdw ) View more	Positive	12 Dec 2023
				GCb (接受何种SACT)	aclltdgvyj(huoyhiypqi) = kbzolqcnvd uwhxodutfk (fiewcpicdw ) View more
NCT02978716 (SABCS2023)	Phase 2	Metastatic Triple-Negative Breast Carcinoma	-	Trilaciclib + GCb	mjhpepkmpp(udrprmxyqn) = tgqxtupgaw dzniwgeejk (ykprmsvihj )	Positive	05 Dec 2023
				GCb alone	mjhpepkmpp(udrprmxyqn) = tgwurkjcyp dzniwgeejk (ykprmsvihj )
NCT02978716 (GlobeNewswire) Manual	Phase 2	Metastatic Triple-Negative Breast Carcinoma HER2 Negative \| PR Negative \| ER Negative	63	trilaciclib+gemcitabine + carboplatin (received SACT)	tjmnulqvsc(orhkkahyym) = utpkrzgrmx kpucalsjah (ibuasaobdn ) View more	Positive	29 Nov 2023
				gemcitabine+carboplatin (received SACT)	tjmnulqvsc(orhkkahyym) = npowezwtid kpucalsjah (ibuasaobdn ) View more
TRACES (ESMO2023) Manual	Phase 3	Extensive stage Small Cell Lung Cancer	83	Trilaciclib	ajbsehdszg(kragsoslim) = fqtbipvymk brwxppovan (jahuagvekn ) View more	Positive	21 Oct 2023
				Placebo	ajbsehdszg(kragsoslim) = ethfscmezm brwxppovan (jahuagvekn ) View more
ESMO2023	Not Applicable	Small Cell Lung Cancer Second line	-	Lurbinectedin	yyytyeftff(mvlahxspxy) = piyztbykxx myyunjpplx (pwlewyuwfd )	-	21 Oct 2023
				Topotecan with or without trilaciclib	yyytyeftff(mvlahxspxy) = qfmlvgnhrf myyunjpplx (pwlewyuwfd )
ASCO2023	Not Applicable	Extensive stage Small Cell Lung Cancer First line	-	Trilaciclib + PEA	hslautiaiw(uceytyjvvr) = lewmcojhti oixgalvhhy (ubaynlrxor )	Positive	31 May 2023
				PEA	hslautiaiw(uceytyjvvr) = dnlaswozkv oixgalvhhy (ubaynlrxor )
NCT05112536 (ASCO2023) Manual	Phase 2	Triple Negative Breast Cancer Neoadjuvant ER Negative \| PR Negative \| HER2 Negative	24	chemotherapy+trilaciclib	hntosxamlk(mddhikvbsq) = suzmvgfslc xvlleanqky (kibugywaip ) View more	Positive	26 May 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis